January 18, 2007 - General Electric Company (NYSE: GE) and Abbott (NYSE: ABT), a global leader in medical diagnostic instruments and tests, announced today that they have entered into a definitive agreement for GE to acquire Abbott’s primary in vitro diagnostics businesses and Abbott Point-of-Care diagnostics business (formerly known as i-STAT) for $8.13 billion in cash. Abbott’s Molecular Diagnostics and Diabetes Care businesses are not part of the transaction and will remain part of Abbott.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now